Myriad Genetics, Inc. Aktie News

Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Myriad announced select unaudited preliminary results for the 4th quarter and full year ended Dec. 31, 2025, provided full year 2026 financial guidance.

SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 5:15 pm PT (8:15 pm ET).

BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens.

SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.

Myriad Genetics (MYGN) is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue growth. MYGN's Hereditary Cancer Test and Prolaris segments show volume growth, but revenue gains remain modest and expansion impacts are delayed. Upcoming addition launches, including expanded MyRisk HCT and AI-powered Prolaris, offer potential but won't affect results until m...

Myriad Genetics, Inc. ( MYGN ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Matthew Scalo - Senior Vice President of Investor Relations Samraat Raha - President, CEO & Director Mark Verratti - Chief Operating Officer Ben Wheeler - CFO & Principal Accounting Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division David Westenberg - P...

Highl ights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds 1 of $8.1 million , consistent with management expectations . Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively.